NCT01858259

Treatment and Prevention of Progression of Interstitial Lung Disease in Systemic Sclerosis

Prevention and Treatment of Interstitial Lung Disease in Systemic Sclerosis

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 1,372 (estimated)
• Sponsor: Gabriela Riemekasten · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

Systemic sclerosis (SSc) is an orphan, multiorgan disease affecting the connective tissue of the skin and all internal organs. Interstitial lung disease is a frequent morbidity and mortality-driving manifestation in systemic sclerosis. This observational trial (OT) is part of the collaborative project "DeSScipher", one out of five OTs to decipher the optimal management of systemic sclerosis. Aim of this observational try is to identify: * The state of clinical practice in Europe for prevention and treatment of interstitial lung disease and its impact on lung function and disease progression * The potential predictors and confounders for response to therapy

Detailed description

Patients are routinely evaluated every 3 months over a 12-months period by medical history, physical examination, pulmonary function tests, VAS lung score and SF-36, SHAQ. Also, their medication and possible medication changes will be recorded.

Conditions

• Systemic Sclerosis
• Interstitial Lung Diseases

Timeline

• Start date: 2013-05-01
• Primary completion: 2016-06-01
• Completion: 2016-06-01
• First posted: 2013-05-21
• Last updated: 2014-08-13

Locations

11 sites across 6 countries: France, Germany, Hungary, Italy, Switzerland, United Kingdom